Loading...

Biotinylated Recombinant Human NKP30/NCR3-Fc Chimera (carrier-free)

Pricing & Availability
Regulatory Status
RUO
Other Names
Activating natural killer receptor NKp30, CD337, naturalcytotoxicity triggering receptor 3, Natural Cytotoxicity TriggeringReceptor 3, CD337 Protein, NCR3 Protein, NKp30 Protein, Activating natural killer receptor p30, CD337 antigen, CD337 activatin
Ave. Rating
Submit a Review
Product Citations
publications
BIOTIN_RECOM_HU-NKP30-NCR3_1_CF
When recombinant human B7-H6-Fc (Cat. No. 794006) is immobilized at 1 µg/mL, Biotinylated Recombinant human NKp30/NCR3 binds in a dose-dependent manner with ED50 of 3 – 18 ng/mL.
  • BIOTIN_RECOM_HU-NKP30-NCR3_1_CF
    When recombinant human B7-H6-Fc (Cat. No. 794006) is immobilized at 1 µg/mL, Biotinylated Recombinant human NKp30/NCR3 binds in a dose-dependent manner with ED50 of 3 – 18 ng/mL.
  • BIOTIN_RECOM_HU-NKP30-NCR3_2_CF
    Stability Testing for Biotinylated Recombinant Human NKp30/NCR3. Biotinylated Recombinant Human NKp30/NCR3 was aliquoted in PBS, pH 7.2. One aliquot was frozen and thawed four times (4x Freeze/Thaw) and compared to a control kept at 4°C (Control). The samples were tested in a binding assay with recombinant human B7-H6-Fc. The ED50 for this effect is 3 – 18 ng/mL.
Cat # Size Price Save
579104 25 µg ¥84,580
579106 100 µg ¥169,150
Description

NKp30 (activating natural killer receptor NKp30), also known as CD337 and Natural Cytotoxicity Triggering Receptor 3 (NCR3), is a member of the natural cytotoxicity receptor (NCR) family. The NCR family are comprised of three type I transmembrane receptors that are expressed almost exclusively by NK cells, includes NKp30, NKp44, and NKp46. NKp30 is a 30 kDa glycosylated protein having one extracellular immunoglobulin-like domain and a hydrophobic TM domain. Six isoforms of NKp30 can be produced by alternative splicing, termed NKp30a-f. NKp30 is expressed on all mature resting and activated NK cells. NKp30 plays an important role in triggering NK cell cytolytic activity. It can enhance NK cell cytolysis of tumor cells that are deficient in MHC class I molecules, either independently or in cooperation with NKp44 and/or NKp46. NKp30 has been reported to have a unique role in NK-mediated lysis of immature dendritic cells. NK cells can kill autologous immature dendritic cells via ligation of NKp30. Alternately, NK cells can also promote the maturation of immature dendritic cells through engagement of NKp30. Heparan Sulfate Glycosaminoglycans, B7-H6, HLA-B-associated transcript 3 (BAT3)/Bcl2-associated anthogene 6 (BAG6), and Galectin-3 were identified as ligands for NKp30. Nkp30 can associate with T cell CD3 receptor zeta (TCRζ) and/or FcRγ via its TM domain with a charged arginine residue. NKp30 also has been shown to associate with CD59. NKp30 may serve as a potential target for therapeutics for cancers, autoimmune, disease atopic diseases, and Infectious diseases.

Product Details
Technical data sheet

Product Details

Source
Biotinylated recombinant human NKp30/NCR3, amino acid Leu19-Thr138 (Accession# O14931.1), with a linker, a C-terminal human IgG1 (Pro100-Lys330) and an Avi-tag, was expressed in 293E cells. Human NKp30/NCR3-Avi tag was site-specifically biotinylated by enzyme BirA.
Molecular Mass
The 372 amino acid recombinant protein has a predicted molecular mass of approximately 41.53 kD. The DTT-reduced and non-reduced protein migrates at approximately 50–70 kD and 80–125 kD by SDS-PAGE, respectively. The predicted N-terminal amino acid is Leu.
Purity
> 95%, as determined by Coomassie stained SDS-PAGE.
Formulation
0.22 µm filtered protein solution is in PBS, pH 7.2
Endotoxin Level
Less than 0.1 EU per µg cytokine as determined by the LAL method.
Concentration
25 µg size is bottled at 200 µg/mL. 100 µg size and larger sizes are lot-specific and bottled at the concentration indicated on the vial. To obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.
Storage & Handling
Unopened vial can be stored between 2°C and 8°C for up to 2 weeks, at -20°C for up to six months, or at -70°C or colder until the expiration date. For maximum results, quick spin the vial prior to opening. Stock solutions should be prepared at no less than 50-100 µg/mL in sterile buffer (PBS, HPBS, DPBS, and EBSS) containing carrier protein such as 0.2 - 1% BSA or HSA and stored in working aliquots at -20°C to -70°C. Avoid repeated freeze/thaw cycles.
Activity
When recombinant human B7-H6-Fc Chimera (Cat. No. 794006) is immobilized at 1 µg/mL, biotinylated recombinant human NKp30/NCR3 binds in a dose-dependent manner with ED50 of 3 – 18 ng/mL.
Application

Bioassay
Application Notes

BioLegend carrier-free recombinant proteins provided in liquid format are shipped on blue-ice. Our comparison testing data indicates that when handled and stored as recommended, the liquid format has equal or better stability and shelf-life compared to commercially available lyophilized proteins after reconstitution. Our liquid proteins are validated in-house to maintain activity after shipping on blue ice and are backed by our 100% satisfaction guarantee. If you have any concerns, contact us at tech@biolegend.com.

Antigen Details

Structure
Dimer
Distribution

IL-2 activated NK cells and NK cell lines, CD8+ T cells, some γ/δ T cells activated in vitro

Function
NK cell triggering of cytolysis toward tumor targets and other target cells deficient in MHC class I molecules
Interaction
K562 cells, cancer cells, dendritic cells
Ligand/Receptor
CRζ, Heparan Sulfate Glycosaminoglycans, B7-H6, BAT3/BAG6, Galectin-3
Bioactivity
Biotinylated recombinant human NKp30 binds to immobilized recombinant human B7-H6 in a dose-dependent manner using a functional ELISA.
Cell Type
NK cells, T cells
Biology Area
Immunology
Molecular Family
CD Molecules
Antigen References
  1. Pende D, et al. 1999. J Exp Med. 15;190:1505-16.
  2. Barrow AD, et al. 2019. Front Immunol. 7:10:909.
  3. Moretta A, et al. 2000. Immunol Today. 21:228-34.
  4. Ferlazzo G, et al. 2002. J Exp Med. 4;195:343-51.
  5. Strandmann E, et al. 2007. Immunity. 27:965-74.
  6. Wang W, et al. 2014. J Biol Chem. 289:33311–33319.
  7. Brandt C, et al. 2009. J Exp Med. 206:1495-503. 
  8. Matta J, et al. 2013. Blood. 122:394-404.
  9. Binici J, 2013. et al. J Biol Chem. 288:34295-303.
Gene ID
259197 View all products for this Gene ID
UniProt
View information about NKP30/NCR3 on UniProt.org

Related FAQs

There are no FAQs for this product.
Go To Top Version: 1    Revision Date: 06/27/2024

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account